Abstract:Aim In 2022, in Italy, general practitioners (GPs) have been allowed to prescribe SGLT2i in Type 2 Diabetes (T2D) under National Health Service (NHS) reimbursement. In the pivotal clinical trial named DECLARE-TIMI 58, dapagliflozin reduced the risk of hospitalization for heart failure, CV death and kidney disease progression compared to placebo in a population of T2D patients. This study evaluated the health and economic impact of dapagliflozin for T2D patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian GPs setting. Methods A budget impact model was developed to assess the health and economic impact of introducing dapagliflozin in GPs setting. The analysis was conducted by adopting the Italian NHS perspective and a 3-year time horizon. The model estimated and compared the health outcomes and direct medical costs associated with a scenario with dapagliflozin and other antidiabetic therapies available for GPs prescription (scenario B) and a scenario where only other antidiabetic therapies are available (scenario A). Rates of occurrence of cardiovascular and renal complications as well as adverse events were captured from DECLARE-TIMI 58 trial and the literature, while cost data were retrieved from the Italian tariff and the literature. One-way sensitivity analyses were conducted to test the impact of model parameters on the budget impact. Results The model estimated around 442.000 patients eligible for the treatment with dapagliflozin in the GPs setting for each simulated year. The scenario B compared to scenario A was associated with a reduction in the occurrence of cardiovascular and renal complication (−1.83%) over the 3 years simulated. Furthermore, the scenario A allowed for an overall cost saving of 102,692,305€: 14,521,464€ in the first year, 33,007,064€ in the second and 55,163,777€ in the third. The cost of cost of drug acquisition, the probability of cardiovascular events and the percentage of patients potentially eligible to the treatment were the factor with largest impact on the results. Conclusions The use of dapagliflozin in GPs setting reduce the number of CVD events, kidney disease progression and healthcare costs in Italy. These data should be considered to optimize the value produced for the T2D patients who had or were at risk for atherosclerotic cardiovascular disease.

An Analysis of the Distribution of Direct Cost of Diabetes Care in Selected Districts in Italy

Burden of Diabetes Mellitus Estimated with a Longitudinal Population-Based Study Using Administrative Databases

Economic Assessment of Direct Cost of Illness of Diabetes Mellitus at Dessie Referral Hospital, North East Ethiopia

Direct and Indirect Cost of Diabetes Care among Patients with Type 2 Diabetes in Private Clinics: a Multicenter Study in Punjab, Pakistan.

The costs of diabetes treatment in low- and middle-income countries: a systematic review

The diabetic patient between sustainability and effectiveness of new treatments

Healthcare Services for Undocumented Migrants: Organisation and Costs from the Italian NHS Perspective

Urban diabetes: analysis of diabetes prevalence in cities of the Lombardy region participating in the cities changing diabetes project

Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study.

Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy

Comprehensive cost-effectiveness of diabetes management for the underserved in the United States: A systematic review

Measures of type 2 diabetes burden in Italy assessed using the AMD dataset over a twelve year span across the Great Recession

Measuring health care access and its inequality: A decomposition approach

Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis

Lifestyle Risk Factors for Type 2 Diabetes Mellitus and National Diabetes Care Systems in European Countries

The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy

[Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study]

A novel comorbidity index in Italy based on diseases detected by the surveillance system PASSI and the Global Burden of Diseases disability weights

Economic cost of diabetes in the Eastern Mediterranean region countries: A meta-analysis

A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries

Addressing chronic diseases: a comparative study of policies towards type-2 diabetes and hypertension in selected European countries